Regeneron Pharmaceuticals (REGN) DIvidends Date & History

Key Takeaways

• Regeneron initiated its first-ever quarterly dividend in February 2025, marking a historic shift in capital allocation for the biotech giant after decades of reinvesting all profits into growth.
• The current dividend yield is approximately 0.45% to 0.60%, making it one of the lowest-yielding dividend stocks in the healthcare sector.
• The payout ratio stands at roughly 8% to 9% of earnings, and about 10% of free cash flow (FCF), leaving enormous headroom for future dividend increases.
• Regeneron raised its quarterly dividend from $0.88 to $0.94 per share in early 2026, a 6.8% increase that signals management's commitment to annual dividend growth.
• With $8.8 billion in cash and marketable securities and robust free cash flow exceeding $3.7 billion annually, the dividend is extremely well-protected.
• The dividend is complemented by an aggressive share buyback program, with a buyback yield near 5.6%, delivering a total shareholder yield above 6%.

Dividend Overview

Regeneron Pharmaceuticals (REGN) is a newcomer to the dividend-paying universe. After more than three decades as a pure-play biotechnology company that channeled every dollar of profit back into research and development (R&D), Regeneron initiated its first quarterly dividend in February 2025 at $0.88 per share. The company currently pays $0.94 per share each quarter, equating to an annualized dividend of $3.76 per share. Based on recent trading prices near $618 to $772 per share, the dividend yield ranges from approximately 0.45% to 0.60%. Regeneron pays dividends quarterly, with ex-dividend dates typically falling around the 20th of February, May, August, and November, and payment dates arriving roughly two weeks later. Given the extremely low yield and newly established payout, REGN is best described as a company with a modest, emerging dividend — not a high-yield or established dividend growth stock, though the trajectory suggests management intends to build that reputation over time.

Dividend History and Growth

Regeneron has no long-term dividend history to evaluate. The company paid its first quarterly dividend of $0.88 per share in February 2025 and maintained that level through four consecutive payments in 2025, totaling $3.52 per share for the year. In early 2026, the board approved a 6.8% increase to $0.94 per share beginning with the February 2026 payment, marking the company's first dividend raise. Prior to 2025, Regeneron had never distributed a dividend, instead using its substantial cash flows to fund internal R&D, strategic collaborations, and share repurchases. This makes REGN a dividend initiation story rather than a dividend growth story. Investors should note that while the first increase is a positive signal, the track record is too short to assess consistency or long-term dividend growth strategy. The company's decision to begin paying a dividend reflects management's confidence in the durability of its blockbuster drug portfolio — including Dupixent, EYLEA HD, and Libtayo — and signals a maturation of the business.

Dividend Sustainability and Payout Ratio

Regeneron's dividend sustainability is exceptionally strong by virtually any measure. With trailing twelve-month (TTM) diluted earnings per share (EPS) of approximately $41, the annual dividend of $3.76 represents a payout ratio of roughly 8% to 9% — among the lowest in the entire stock market. On a free cash flow basis, the coverage is similarly robust: Regeneron generated approximately $3.8 billion to $4.1 billion in FCF over the past year, while total annual dividend payments amount to roughly $400 million, implying an FCF payout ratio of about 10%. The company also holds approximately $8.8 billion in cash and marketable securities against modest long-term debt, providing a fortress-like balance sheet that further insulates the dividend from any earnings volatility. Even in a scenario where earnings declined by 50%, the dividend would remain comfortably covered. Put simply, Regeneron's dividend is not just sustainable — it has one of the widest margins of safety of any dividend-paying stock in the healthcare sector.

Dividend Compared to Industry Peers

Within the biotechnology and large-cap pharmaceutical space, Regeneron's dividend profile is distinct. Established biotech dividend payers such as AMGN (Amgen) and GILD (Gilead Sciences) offer yields in the 3% to 4% range with decade-plus track records of consistent dividend growth. By contrast, several of Regeneron's closest biotech peers — including VRTX (Vertex Pharmaceuticals) and BIIB (Biogen) — pay no dividend at all. This places REGN in a middle ground: it now returns cash to shareholders through dividends, which distinguishes it from non-payers, but its yield is far below that of mature, dividend-focused pharmaceutical companies. Regeneron's total shareholder return strategy also leans heavily on buybacks; its buyback yield of approximately 5.6% dwarfs the dividend yield and brings total shareholder yield above 6%, a figure that is competitive with or exceeds many high-dividend pharma peers when both forms of capital return are considered together.

AI Screener

For investors seeking to identify dividend-paying stocks, emerging income opportunities, or companies with strong free cash flow coverage like Regeneron, Tickeron's AI Screener offers a powerful, AI-driven solution. The AI Screener allows users to filter thousands of stocks and ETFs using customizable criteria such as industry, market capitalization, dividend yield, payout ratio, technical indicators, and AI-generated trading signals. Rather than manually sifting through financial statements and price charts, investors can use the platform to scan for dividend initiators, consistent dividend growers, or stocks with unusually low payout ratios that signal room for future increases. The screener also supports pattern recognition and volatility-based filters, helping traders spot breakout candidates and trend shifts. By combining fundamental and technical analysis in one tool, the AI Screener makes market research significantly more efficient — whether you are building an income portfolio or hunting for the next dividend growth story.

Is This Stock Attractive for Dividend Investors?

Regeneron is not a conventional dividend stock, and it will not appeal to investors who depend on dividend income for living expenses. With a yield below 1%, REGN offers negligible immediate income. However, the stock may hold significant appeal for a different type of dividend investor: those focused on dividend growth potential and total return. The ultra-low payout ratio suggests that Regeneron has decades of runway to increase its dividend at a high rate — potentially 10% or more annually — without straining earnings or free cash flow. For patient, long-term investors who prioritize dividend safety and future growth over current income, REGN represents a compelling case. The dividend also functions as a signal of management discipline and shareholder-friendly capital allocation, which total-return-oriented investors may value. Investors seeking current income should look elsewhere. Those who want exposure to a financially robust biotech franchise with an emerging dividend and massive buyback program may find REGN worth a closer look. As always, individual circumstances and portfolio goals should guide any investment decision.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations